Pharvaris (NASDAQ:PHVS) Shares Bought by Bank of America Corp DE

Bank of America Corp DE raised its position in shares of Pharvaris (NASDAQ:PHVS - Free Report) by 205,286.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 30,808 shares of the company's stock after purchasing an additional 30,793 shares during the quarter. Bank of America Corp DE owned 0.06% of Pharvaris worth $591,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in PHVS. FMR LLC grew its stake in Pharvaris by 3.6% during the 4th quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after purchasing an additional 189,714 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after buying an additional 118,408 shares during the period. Northern Trust Corp increased its holdings in Pharvaris by 483.9% in the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company's stock worth $1,762,000 after buying an additional 76,188 shares during the period. Rock Springs Capital Management LP increased its holdings in Pharvaris by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock worth $14,859,000 after buying an additional 18,200 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new position in Pharvaris in the 4th quarter worth approximately $196,000.

Wall Street Analysts Forecast Growth

PHVS has been the topic of several research reports. Cantor Fitzgerald cut their price target on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Guggenheim started coverage on shares of Pharvaris in a report on Wednesday. They issued a "buy" rating and a $32.00 price target on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $27.00 price objective on shares of Pharvaris in a report on Thursday, June 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $36.20.

Pharvaris Stock Down 3.1%

Shares of PHVS stock traded down $0.53 on Friday, hitting $16.70. The company had a trading volume of 12,409 shares, compared to its average volume of 74,118. The firm has a market cap of $873.24 million, a P/E ratio of -5.96 and a beta of -2.86. The company has a 50-day moving average price of $15.93 and a 200-day moving average price of $16.90. Pharvaris has a twelve month low of $11.51 and a twelve month high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.09). Equities research analysts expect that Pharvaris will post -2.71 EPS for the current year.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.